drugset / Trial / NCT00694200
Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
Phase 2
Terminated
13 enrolled
Hellenic Oncology Research Group
University Hospital of Crete · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy of metronomic oral vinorelbine taken three times a week without break plus bevacizumab as salvage treatment in patients with metastatic breast cancer.
Timeline
- Start
- 2008-04
- Primary completion
- 2009-12
- Completion
- 2009-12
Outcome
Outcome not reported
Stopped: “Not reached the statistical hypothesis at the interim analysis”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Vinorelbine | Small molecule | 50 mg | Oral |